Home › Compare › AVDWF vs ABBV
AVDWF yields 13.77% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 2
Combined, AVDWF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AVDWF + ABBV for your $10,000?
Advent-AWI Holdings Inc., together with its subsidiaries, sells cellular and wireless products, services, and accessories in Canada. It operates through three segments: Wireless Business, Financing Business, and Digital Health Business. The Wireless Business segment offers wireless voice and data, high speed internet, digital cable television, home phone, smart home monitoring, and Rogers Bank Mastercard products. As of December 31, 2021, it had 4 stores, including 2 Rogers and 2 Fido stores in Ontario. The Financing Business segment provides personal and collateral loans across the Greater Vancouver and Greater Toronto Areas. The Digital Health Business segment offers digital health products and services, including handheld health scanners, which are wirelessly connected with cloud based artificial intelligence through channel customized software and mobile applications to monitor heart rate, blood pressure, blood oxygen saturation levels, respiratory lung analysis, body temperature, and body composition; and IT support services to consumers and health care providers in Hong Kong and Macau. The company was formerly known as Advent Wireless Inc. and changed its name to Advent-AWI Holdings Inc. in March 2017. Advent-AWI Holdings Inc. was incorporated in 1984 and is based in Vancouver, Canada.
Full AVDWF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.